Azarbine composition
US5023083A · kind A · utility
25Cited by
0References
32Claims
0Family size
Inventor
Key dates
| Filing date | Jan 12, 1990 |
| Grant date | Jun 11, 1991 |
| Priority date | — |
| Expiry date | Jan 12, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating azaribine-responsive diseases in patient's who exhibit severe pyridoxal phosphate depletion following the oral administration of azaribine comprises first encapsulating azaribine in a film-forming substance which is selectively soluble in the digestive juice of the intestines. The encapsulated azaribine is then orally administered to the patient in an amount effective for the treatment of the disease, preferably in an amount to provide from about 1.5 to about 15 grams of azaribine per square meter of patient body surface area per day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.